source
- U.S. 'most-favored nations' policy prompts drugmakers to reconsider overseas launchesThe White House's "most-favored nations" rule, which would tie foreign drug prices to U.S. prices, is causing U.S. pharma firms to rethink launching products abroad. Companies are exploring strate…
- Federal panel overseeing preventive care receives blanket ethics waivers despite members' pharma and practice conflictsFederal officials granted blanket ethics waivers to every member of the U.S. Preventive Services Task Force, allowing them to serve despite clear financial conflicts of interest. Documents show so…